

Pharmaceutical Pipeline – Key Events in 2018*

Potential Approvals US/EU	Apalutamide	– Pre-metastatic prostate cancer (US)
	JULUCA® (Ralpivirine+dolutegravir FDC ViiV)	– HIV (EU)
	SYMTUZA™	– HIV (US)
	DARZALEX®	– Frontline multiple myeloma nontransplant (US/EU)
	XARELTO®	– CAD/PAD (US)
	INVOKANA®	– CANVAS/CANVAS-R–CV outcome (US/EU)
	ZYTIGA®	– Hormone-naïve metastatic prostate cancer (US)
	IMBRUVICA®	– Combo w/rituximab TN WM (US)

Planned Submissions US/EU	Esketamine	– Treatment-resistant depression (US/EU)
	Erdafitinib	– Solid tumors (US/ EU)
	XARELTO®	– Congestive heart failure (US)
	Apalutamide	– Pre-metastatic prostate cancer (EU)
	Apalutamide + abiraterone acetate	– Chemo-naïve prostate cancer (US/EU)
	IMBRUVICA®	– DLBCL frontline (US/EU) – Frontline CLL combination (US/EU) – Combo w/rituximab TN WM (US/EU)
OPSUMIT®	– Chronic thromboembolic PH (US/EU)	

Potential Clinical Data Presentations Phase 3	XARELTO®	– VTE prevention medically ill pts (MARINER) – Congestive heart failure (COMMANDER)
	STELARA®	– Ulcerative Colitis
	TREMFYA®	– Psoriasis (ORION)
	Esketamine	– Treatment Resistant Depression
	Apalutamide	– pre-metastatic prostate cancer (SPARTAN)
	DARZALEX®	– Frontline multiple myeloma non-transplants (MAIA)
	SYMTUZA™	– HIV
	IMBRUVICA®	– Frontline CLL combo (PCYC1130) – DLBCL frontline (PHOENIX) – Combo w/rituximab TN WM (iNOVATE)

Potential Clinical Data Presentations Phase 2	HIV Vaccine	– HIV (ASCENT) – HIV (TRAVERSE)
	IMBRUVICA®	– DLBL relapsed (PCYC1123) – Frontline CLL (IV fixed duration) (PCYC1142)
	DARZALEX®	– Frontline multiple myeloma transplants (GRIFFIN)
	Erdafitinib	– Metastatic urothelial cancer (BLC2001)

* This information is accurate as of January 23, 2018 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.